Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
GE Healthcare recently announced that Clarient Diagnostic Services, Inc., a GE Healthcare company, will begin offering a next-generation sequencing assay focused on solid tumor targets for use in clinical trials. This assay will empower researchers to perform prospective and retrospective analysis to better understand which patients will respond to particular therapies, to help stratify patient populations for ongoing clinical trials, and to aid early research efforts. 
No comment yet.
Sign up to comment
Scoop.it!
Heidi Rehm has been using disease-targeted gene panels to diagnose patients in her clinical molecular genetics practice for a decade. Having adopted next-generation sequencing approaches two years ago, and whole-genome and whole-exome sequencing for some patients in the past year, she is a pioneer in applying genomics in the clinic. Via Brian Shields
Brian Shields's curator insight,
February 12, 2013 11:36 PM
Very good discussion on the current impact that genetic and genomic sequencing are having on clinical decisions, and a look into the future when genome analysis is much more cost effective.
Scoop.it!
I’m sick of reading about the dangers of the genome. There are lots of popular articles I could point to, but let’s start with a recent series in Time that included eight online features and the Dec. 13 cover story, ominously titled “The DNA Dilemma.”
The series, written by Bonnie Rochman, is thoroughly reported, balanced, and full of fascinating personal stories about children whose genomes have been sequenced. It’s also timely: The primary question Rochman raises—how much information is too much information?—has been dominating commentaries about genetic testing in the medical literature.
But this is the wrong question, or at least one that’s becoming increasingly irrelevant.
Ray and Terry's 's insight:
With the wealth of genetic information (at a reasonable price) available to the public, there are ethical questions that arise. Some might panic about individuals having too much information about their own DNA, but this author suggests that we can handle it.
|
Scoop.it!
Scientists have for the first time mapped the genomes of tapeworms, shedding light on the evolution of one of humankind's oldest parasites and revealing new possibilities for drug treatments.
DNA analysis of the tapeworms suggests that a number of existing medicines for cancer, viruses and other diseases may be able to fight serious illness caused by their larvae, which can spread through the body causing damaging cysts.
Scoop.it!
Embracing the promise of personalized medicine, Fox Chase Cancer Center is offering a high-tech DNA test that can identify the genetic mutations driving an individual patient's cancer. Via Brian Shields
Brian Shields's curator insight,
February 4, 2013 5:44 PM
This is a great step forward in the treatment of cancer by Fox Chase Cancer Center. Hopefully in the future, similar offerings will become the standard of care.
Scoop.it!
When you look at your body in the mirror, most of what you consider to be “you” actually isn’t you, at least not in a biological sense. That’s because there are approximately 10 bacterial cells for every single human cell in the body.
|
